The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores

• Published in: Annals of surgery 1992-10, Vol.216 (4), p.401-408
• Main Authors: Robson, M C, Phillips, L G, Lawrence, W T, Bishop, J B, Youngerman, J S, Hayward, P G, Broemeling, L D, Heggers, J P
• Format: Article
• Language: English
• Subjects: Administration, Topical; Adolescent; Adult; Aged; Female; Fibroblast Growth Factor 2 - administration & dosage; Fibroblast Growth Factor 2 - adverse effects; Humans; Male; Middle Aged; Pressure Ulcer - therapy; Recombinant Proteins
• ISSN: 0003-4932; 1528-1140
• DOI: 10.1097/00000658-199210000-00002

The first randomized, blinded, placebo-controlled human trials of recombinant basic fibroblast growth factor (bFGF) for pressure sore treatment were performed. Three different concentrations of bFGF in five dosing schedules were tested for safety using hematology, serum chemistries, urinalysis, absorption, antibody formation, and signs of toxicity. Efficacy was evaluated by wound volumes, histology, and photography. No toxicity, significant serum absorption, or antibody formation occurred. In six of eight subgroups, there was a trend toward efficacy with bFGF treatment. When all subgroups were combined, comparison of the slopes of the regression curves of volume decrease over initial pressure sore volume demonstrated a greater healing effect for the bFGF-treated patients (p < 0.05). Histologically, bFGF-treated wound sections demonstrated increased fibroblasts and capillaries. More patients treated with bFGF achieved > 70% wound closure (p < 0.05). Blinded observers were able to distinguish differences in visual wound improvement between bFGF and placebo groups. These data suggest that bFGF may be effective in the treatment of chronic wounds.